Active Biotech provides status update in the portfolio projects

PRESS RELEASE

Presentation - new direction

New pre-clinical data on laquinimod in an experimental autoimmune uveitis model has been published as an abstract in the Jornal of Immunology. May 1, 2020, 204 (1 Supplement) 150.18.

Laquinimod

Annual General Meeting of Active Biotech AB

PRESS RELEASE

Annual Report 2019

Download the PDF

Active Biotech AB - Interim Report January - March 2020

PRESS RELEASE

Notice of annual general meeting of shareholders

PRESS RELEASE

Active Biotech announces new direction

PRESS RELEASE

Develops Novel Treatments for Cancer and Inflammatory Diseases

ABOUT US

An Experienced Team — Building Solid Partnerships

MANAGEMENT

Novel immunomodulatory treatments for patients with cancer or inflammatory diseases

Active Biotech focuses on the research and development of pharmaceuticals in therapeutic areas in which the immune system is of central importance. The project portfolio comprises therapy developed for the treatment of cancer and inflammatory diseases.

Diseases where the immune system is of central importance